, Volume 19, Issue 3, pp 91–100 | Cite as

Comprehensive lifestyle interventions in the community: A preliminary analysis

  • Gary Null
  • Martin Feldman


In a 6-month prospective study designed to retard the aging process, we examined the effects of comprehensive lifestyle modifications in 52 participants aged 31 to 78 years, who were free of clinically overt disease. The group adhered to a low-fat vegetarian diet supplemented with antioxidant nutrients, engaged in regular aerobic exercise (power-walking or jogging), and received motivational support. Statistical analysis of objective data shows a trend of optimization of weight and lipid values. Overall, the group lost an average of 2.95 kg, or 4.4% of starting weight; total cholesterol (TC) decreased 7.7%; LDL-C, 12%; and TC/HDL-C ratio, 9%. Analysis by age and gender shows no significant differences in trends. When grouped by objective parameter, maximal effect is found in those with greatest deviation from a normal value at baseline. Subjective assessments showed significant improvement in energy levels and physiological functioning. Although more well-defined studies are needed, we conclude that lifestyle modifications can optimize health status and level of physiologic functioning, and may be instituted by adults of all age groups with prior medical approval.


Aging Process Aerobic Exercise Objective Data Lifestyle Intervention Subjective Assessment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kannel WB, Wilson PW.: Efficacy of lipid profiles in prediction of coronary disease. Am Heart J. 1992;124:768–774.PubMedCrossRefGoogle Scholar
  2. 2.
    Rose G.: Strategy of prevention: lessons from cardiovascular disease. Br Med J. 1981; 282: 1847–51.Google Scholar
  3. 3.
    Ferrini RL, Edelstein SL, Barrett-Connor E.: Factors associated with health behavior change among residents 50 to 96 years of age in Rancho Bernardo, California. Am J Prev Med. 1994;10:26–30.PubMedGoogle Scholar
  4. 4.
    McGinnis JM.: Prevention in 1989: the state of the nation. Am J Prev Med. 1990;6:1–5.PubMedGoogle Scholar
  5. 5.
    Salonen JT, Salonen R, Seppanen K, et al.: Interactions of serum copper, selenium, and low density lipoprotein cholesterol in atherogenesis. Br Med J. 1991;302:756–760.Google Scholar
  6. 6.
    Kok FJ.: Antioxidants and risk of myocardial infarction. Acta Cardiol. 1993;48:456–7.PubMedGoogle Scholar
  7. 7.
    Rimm EB, Stampfer MJ, Ascherio A, et al.: Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993;328:1450–1456.PubMedCrossRefGoogle Scholar
  8. 8.
    Stampfer MJ, Hennekens CH, Manson JE, et al.: Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993;328:1444–9.PubMedCrossRefGoogle Scholar
  9. 9.
    The Carter Center of Emory University, Health Policy Consultation. Closing the gap: health policy project interim summary. 1984; B99,B34,B20.Google Scholar
  10. 10.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015–3023.CrossRefGoogle Scholar
  11. 11.
    Kronhausen E, Kronhausen P, Demopoulos HB.: Formula for Life. William Morrow and Co. New York, 1989:95.Google Scholar
  12. 12.
    Gaby SK, Singh VN.: Vitamin C in Vitamin Intake and Health: A Scientific Review, Gaby SK, Bendich A, Singh V, Machlin L (eds). Marcel Dekker, New York, 1991.Google Scholar
  13. 13.
    Bland J.: The nutritional effects of free radical pathology. In: 1986/A Year in Nutritional Medicine Monograph. Keats Publishing Inc., New Canaan, CT.Google Scholar
  14. 14.
    Vitamin E strengthens the immune system in elderly patients. Drug Topics. February 18, 1991, 135: 38.Google Scholar
  15. 15.
    Null G, Feldman M.: Reverse the Aging Process Naturally. New York: Random House Inc; 1993. p 269.Google Scholar
  16. 16.
    Hocman G.: Chemoprevention of cancer: selenium. Int J Biochem. 1988;20:123–132.PubMedCrossRefGoogle Scholar
  17. 17.
    Bendrich A.: Antioxidant micronutrients and immune responses. In: Bendich A, Chandra RK, eds: Micronutrients and Immune Function. Annals New York Academy of Sciences. New York, 1990.Google Scholar
  18. 18.
    Cody V, Middleton E, Harborne JB.: Plant Flavonoids in Biology and Medicine — Biochemical, Pharmacological, and Structure-Activity Relationships. Alan R. Liss, New York, NY. 1986.Google Scholar
  19. 19.
    Havsteen B.: Flavonoids, a class of natural products of high pharmacological potency. Biochem Pharmacol. 1983;32:1–148.CrossRefGoogle Scholar
  20. 20.
    Middleton E.: The flavonoids. Trends Pharmaceut Sci. 1984;5:335–338.Google Scholar
  21. 21.
    Null G.: Change Your Life Now. Deerfield Beach, Fla: Health Communications, Inc; 1993:1–182.Google Scholar
  22. 22.
    Castelli WP, Anderson K.: A population at risk: prevalence of high cholesterol levels in hypertensive patients in the Framingham Study. Am J Med. 1986;80(suppl 2A):23–32.PubMedCrossRefGoogle Scholar
  23. 23.
    National Health Laboratories; source: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Arch Intern Med. 1988;148: 36–69.CrossRefGoogle Scholar
  24. 24.
    Frick MH, Elo O, Haapa K, et al.: Helsinki Heart Study Primary Prevention Trial with gemfibrozil in middle-aged men with dyslipidemia. N EnglJ Med. 1987;317:1237–1244.CrossRefGoogle Scholar
  25. 25.
    Lipid Research Clinics Program: The Lipid Research Clinics Coronary Primary Prevention Trial Results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984; 251:365–374.CrossRefGoogle Scholar
  26. 26.
    Hellenius ML, de Faire U, Berglund B, Hamsten A, Krakau I.: Diet and exercise are equally effective in reducing risk for cardiovascular disease. Results of a randomized controlled study in men with slightly to moderately raised cardiovascular risk factors. Atherosclerosis. 1993; 103:81–91.PubMedCrossRefGoogle Scholar
  27. 27.
    Wood PD, Stefanick ML, Dreon DM, Frey-Hewitt B, et al.: Changes in plasma lipids and lipoproteins in overweight men during weight loss through dieting as compared with exercise. N Engl J Med. 1988;319:1173–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Paffenbarger RS Jr, Hale WE.: Work activity and coronary heart mortality. N Engl J Med. 1975; 292:545–550.PubMedCrossRefGoogle Scholar
  29. 29.
    Morris JN, Everitt MG, Pollard R, et al.: Vigorous exercise in leisure-time: protection against coronary heart disease. Lancet. 1980;2:1207–1210.PubMedCrossRefGoogle Scholar
  30. 30.
    Dufaux B, Assmann G, Hollmann W.: Plasma lipoproteins and physical activity: a review. IntJ Sports Med. 1982;3:123–136.CrossRefGoogle Scholar
  31. 31.
    Mersy DJ.: Health benefits of aerobic exercise. Postgrad Med. 1991;90:103–112.PubMedGoogle Scholar
  32. 32.
    Jennings G, Nelson L, Nestel P, et al.: The effects of changes in physical activity on major cardiovascular risk factors, hemodynamics, sympathetic function, and glucose utilization in man: a controlled study of four levels of activity. Circulation. 1986;73:30–40.PubMedGoogle Scholar
  33. 33.
    Superko HR.: Exercise training, serum lipids, and lipoprotein particles: is there a change threshold? Med Sci Sports Exerc 1991;23:677–85.PubMedGoogle Scholar
  34. 34.
    Shepard RJ.: Nutritional benefits of exercise. J Sports Med Phys Fitness. 1989;29:83–90.Google Scholar
  35. 35.
    Reid CM, Dart AM, Dewar EM, Jennings GL.: Interactions between the effects of exercise and weight loss on risk factors, cardiovascular haemodynamics and left ventricular structure in overweight subjects. J Hypertens 1994; 12:291–301.PubMedGoogle Scholar
  36. 36.
    Salonen JT.: The role of lipid peroxidation, antioxidants and pro-oxidants in atherosclerosis. Acta Cardiol. 1993;48:457–459.PubMedGoogle Scholar
  37. 37.
    Maxwell SR.: Can anti-oxidants prevent ischaemic heart disease? J Clin Pharm Ther. 1993; 18: 85–95.PubMedGoogle Scholar
  38. 38.
    Singh RB, Niaz MA, Gosh S, Singh R, Rastogi SS.: Effect on mortality of adding fruits and vegetables to a prudent diet in the Indian experiment of infarct survival (IEIS). J Am Coil Nutr. 1993; 12:255–261.Google Scholar
  39. 39.
    Maxwell SR, Jakeman P, Thomason H, Leguen C, Thorpe GH.: Changes in plasma antioxidant status during eccentric exercise and the effect of vitamin supplementation. Free Radic Res Commun. 1993; 19:191–202.PubMedGoogle Scholar
  40. 40.
    Ornish D, Brown SE, Scherwitz LW, et al.: Can lifestyle changes reverse coronary heart disease? Lancet. 1990;336:129–133.PubMedCrossRefGoogle Scholar
  41. 41.
    Levy RI, Brensike JF, Epstein SE, et al.: The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease. Circulation. 1984;69:325–337.PubMedGoogle Scholar
  42. 42.
    Blankenhorn DW, Nessim SA, Johnson RL, et al.: Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233–3240.PubMedCrossRefGoogle Scholar
  43. 43.
    Brown G, Albers JJ, Fisher LD, et al.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323: 1289–1295.CrossRefGoogle Scholar
  44. 44.
    Levy RI, Treondle AJ, Fattu JM.: A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation. 1993;87(4 Suppl):III-45–III-53.Google Scholar
  45. 45.
    Hay JW, Wittels EH, Gotto Jr, AM.: An economic evaluation of Iovastatin for cholesterol lowering and coronary artery disease reduction. Am J Cardiol. 1991;67:789–796.PubMedCrossRefGoogle Scholar
  46. 46.
    Kinlay S, O’Connell D, Evans D, Halliday J.: A new method of estimating cost effectiveness of cholesterol reduction therapy for prevention of heart disease. PharmacoEconomics. 1994;5:238–248.PubMedGoogle Scholar
  47. 47.
    Sempos CT, Cleeman JI, Carroll MD, et al.: Prevalence of high blood cholesterol among US adults: an update based on guidelines from the second Report of the National Cholesterol Education Program Adult Treatment Panel. JAMA. 1993;269:3009–3014.PubMedCrossRefGoogle Scholar
  48. 48.
    Ramsey LE, Yeo WW, Jackson PR.: Dietary reduction of serum cholesterol concentration: time to think again. Br Med J. 1991;303:953–057.CrossRefGoogle Scholar
  49. 49.
    Kannel WB.: Low high-density lipoprotein cholesterol and what to do about it. Am J Cardiol. 1992; 70:810–814.PubMedCrossRefGoogle Scholar

Copyright information

© American Aging Association, Inc. 1996

Authors and Affiliations

  • Gary Null
    • 1
  • Martin Feldman
    • 2
  1. 1.Center for Postgraduate and Continuing EducationNew York College of ChiropracticUSA
  2. 2.New York

Personalised recommendations